Avidity Biosciences (RNA) Total Current Liabilities (2019 - 2025)
Historic Total Current Liabilities for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to $169.9 million.
- Avidity Biosciences' Total Current Liabilities rose 8599.96% to $169.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $169.9 million, marking a year-over-year increase of 8599.96%. This contributed to the annual value of $98.0 million for FY2024, which is 2148.98% up from last year.
- Per Avidity Biosciences' latest filing, its Total Current Liabilities stood at $169.9 million for Q3 2025, which was up 8599.96% from $135.1 million recorded in Q2 2025.
- In the past 5 years, Avidity Biosciences' Total Current Liabilities ranged from a high of $169.9 million in Q3 2025 and a low of $16.3 million during Q2 2021
- Over the past 5 years, Avidity Biosciences' median Total Current Liabilities value was $48.7 million (recorded in 2023), while the average stood at $63.5 million.
- Its Total Current Liabilities has fluctuated over the past 5 years, first soared by 10618.8% in 2022, then soared by 1322.13% in 2025.
- Quarter analysis of 5 years shows Avidity Biosciences' Total Current Liabilities stood at $29.7 million in 2021, then soared by 75.02% to $51.9 million in 2022, then skyrocketed by 55.43% to $80.7 million in 2023, then rose by 21.49% to $98.0 million in 2024, then soared by 73.31% to $169.9 million in 2025.
- Its Total Current Liabilities stands at $169.9 million for Q3 2025, versus $135.1 million for Q2 2025 and $84.9 million for Q1 2025.